Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. is positioned for a positive financial outlook due to its potential for robust revenue growth, driven by accelerating market share gains in the minimally invasive glaucoma surgery (MIGS) sector and increased adoption of the TearCare System. The company's investment thesis highlights that its Surgical Glaucoma segment is expected to maintain growth consistent with the overall MIGS market, ensuring a solid revenue foundation. Additionally, improvements in earnings per share (EPS) for 2025 and 2026 indicate a trend toward increased profitability, further reinforcing the optimistic financial projections for the company.

Bears say

Sight Sciences Inc. continues to project 2025 revenues in the range of $72-76 million while anticipating a mid-single-digit percentage decline in Surgical Glaucoma revenue for the third quarter of 2025 compared to the prior year. The company faces significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, slow progress in securing insurance coverage for its TearCare product, and a persistent elevated cash burn rate that may hinder financial stability. Furthermore, although management has reduced its adjusted operating expense guidance for 2025 to $95-99 million from a previous $101-105 million, the expected $12 million in annualized savings may not sufficiently offset the declining revenue expectations.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.